SINGAPORE, May 9, 2023 /PRNewswire/ CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today announced it has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center ("MD Anderson").
/PRNewswire/ CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a pre-clinical biopharmaceutical company focused on developing novel.
Revenues grew by 32.2% as real-time video communication solutions see wider adoption and penetrate new vertical marketsBEIJING, April 18, 2023 /PRNewswire/ Baijiayun Group Ltd , a. | April 18, 2023
/PRNewswire/ Baijiayun Group Ltd ("Baijiayun" or the "Company") (Nasdaq: RTC), a video-centric technology solution provider with core expertise in SaaS/PaaS.